Clinical Trial Update: Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Uprifosbuvir + Ruzasvir for hepatitis C genotypes 1-6; study terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ruzasvir (ruzasvir)
• Uprifosbuvir (uprifosbuvir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 2 | Status: TERMINATED | Results posted: 2018-12-26